Percutaneous management of valvular heart disease is becoming a reality, with multicenter trials supporting minimally invasive procedures for both aortic and mitral valve disease. Historically, the treatment of choice has been aortic valve replacement with conventional surgery for patients with severe aortic stenosis, as the prognosis of untreated patients is poor, particularly if the patient is symptomatic. Transcatheter aortic valve replacement is now available as a minimally invasive option to treat select high-risk patients with severe aortic stenosis. At present more than 30,000 procedures have been performed worldwide, mostly confined to patients at high surgical risk. The short- and medium-term outcomes have been promising.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ccl.2011.10.003 | DOI Listing |
Front Cardiovasc Med
December 2024
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bicuspid aortic valve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration. Abnormal hemodynamics, arterial wall characteristics, and genetic factors contribute to ascending aorta dilatation, potentially leading to severe complications like aortic dissection. Presently, the most recent guidelines propose that individuals with BAV requiring valve replacement due to valve dysfunction should undergo simultaneous replacement of the ascending aorta when the diameter of aortic dilatation exceeds 4.
View Article and Find Full Text PDFJ Surg Res
December 2024
Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address:
Introduction: Transcatheter aortic valve replacement (TAVR) has become a viable alternative to surgical aortic valve replacement (SAVR) for high-risk patients with aortic stenosis. One such high-risk group is patients with pulmonary hypertension (PH), which is known to increase surgical risk and adversely affect outcomes. This study aims to compare midterm and long-term survival in TAVR and SAVR among patients with PH.
View Article and Find Full Text PDFBiomech Model Mechanobiol
December 2024
Institute for Biomedical Engineering and Nano Science, Shanghai East Hospital, Tongji University School of Medicine, 500 Zhennan Road, Shanghai, 200331, People's Republic of China.
Hypertension and bicuspid aortic valve (BAV) are key clinical factors that may affect local biomechanical properties of ascending thoracic aortic aneurysms (ATAAs). This study sought to investigate regional differences in biaxial mechanical properties of the ATAAs for the hypertensive patients with BAV. Fresh ATAA samples were harvested from 16 hypertensive patients (age, 66 ± 9 years) undergoing elective aortic surgery.
View Article and Find Full Text PDFRev Esp Cardiol (Engl Ed)
December 2024
Département de Cardiologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, Canada. Electronic address:
Introduction And Objectives: The Valve Academic Research Consortium (VARC)-3 definition of the early safety (ES) composite endpoint after transcatheter aortic valve replacement (TAVR) lacks clinical validation. The aim of this study was to determine the incidence, predictors, and clinical impact of ES after TAVR as defined by VARC-3 criteria.
Methods: We performed a multicenter study including 10 078 patients with severe aortic stenosis undergoing transarterial TAVR.
JACC Cardiovasc Interv
December 2024
Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, RGDS (Ramsay Generale De Santé), Massy, France. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!